156 related articles for article (PubMed ID: 36529989)
21. KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
Diehl AC; Hannan LM; Zhen DB; Coveler AL; King G; Cohen SA; Harris WP; Shankaran V; Wong KM; Green S; Ng N; Pillarisetty VG; Sham JG; Park JO; Reddi D; Konnick EQ; Pritchard CC; Baker K; Redman M; Chiorean EG
Oncologist; 2022 Dec; 27(12):1025-1033. PubMed ID: 36124727
[TBL] [Abstract][Full Text] [Related]
22. Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.
Bisht S; Ahmad F; Sawaimoon S; Bhatia S; Das BR
Med Oncol; 2014 Sep; 31(9):124. PubMed ID: 25073438
[TBL] [Abstract][Full Text] [Related]
23. ProTarget: a Danish Nationwide Clinical Trial on Targeted Cancer Treatment based on genomic profiling - a national, phase 2, prospective, multi-drug, non-randomized, open-label basket trial.
Kringelbach T; Højgaard M; Rohrberg K; Spanggaard I; Laursen BE; Ladekarl M; Haslund CA; Harsløf L; Belcaid L; Gehl J; Søndergaard L; Eefsen RL; Hansen KH; Kodahl AR; Jensen LH; Holt MI; Oellegaard TH; Yde CW; Ahlborn LB; Lassen U
BMC Cancer; 2023 Feb; 23(1):182. PubMed ID: 36814246
[TBL] [Abstract][Full Text] [Related]
24. Differential properties of KRAS transversion and transition mutations in non-small cell lung cancer: associations with environmental factors and clinical outcomes.
Sato K; Akamatsu H; Koh Y; Ogawa K; Isa SI; Ando M; Tamiya A; Kubo A; Kitagawa C; Kawaguchi T; Yamamoto N
BMC Cancer; 2022 Nov; 22(1):1148. PubMed ID: 36348317
[TBL] [Abstract][Full Text] [Related]
25. Prevalence of KRAS p.(G12C) in stage IV NSCLC patients in the Netherlands; a nation-wide retrospective cohort study.
Garcia BNC; van Kempen LC; Kuijpers CCHJ; Schuuring E; Willems SM; van der Wekken AJ
Lung Cancer; 2022 May; 167():1-7. PubMed ID: 35349855
[TBL] [Abstract][Full Text] [Related]
26. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
[TBL] [Abstract][Full Text] [Related]
27. Non-canonical genomic driver mutations of urethane carcinogenesis.
Li S; Counter CM
PLoS One; 2022; 17(4):e0267147. PubMed ID: 35482806
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients.
Chen J; Guo F; Shi X; Zhang L; Zhang A; Jin H; He Y
BMC Cancer; 2014 Nov; 14():802. PubMed ID: 25367198
[TBL] [Abstract][Full Text] [Related]
29. Malfeasance of KRAS mutations in carcinogenesis.
Tripathi R; Nathany S; Mehta A; Batra U; Mattoo S; Sharma M
Clin Exp Med; 2021 Aug; 21(3):439-445. PubMed ID: 33709341
[TBL] [Abstract][Full Text] [Related]
30. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
31. Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients.
Bhaumik S; Ahmad F; Das BR
Med Oncol; 2016 Oct; 33(10):117. PubMed ID: 27637917
[TBL] [Abstract][Full Text] [Related]
32. Effects of Co-occurring Genomic Alterations on Outcomes in Patients with
Arbour KC; Jordan E; Kim HR; Dienstag J; Yu HA; Sanchez-Vega F; Lito P; Berger M; Solit DB; Hellmann M; Kris MG; Rudin CM; Ni A; Arcila M; Ladanyi M; Riely GJ
Clin Cancer Res; 2018 Jan; 24(2):334-340. PubMed ID: 29089357
[No Abstract] [Full Text] [Related]
33. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
Parums DV
Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
[TBL] [Abstract][Full Text] [Related]
34. Mutational Landscape and Expression of PD-L1 in Patients with Non-Small Cell Lung Cancer Harboring Genomic Alterations of the MET gene.
Fischer A; Bankel L; Hiltbrunner S; Rechsteiner M; Rüschoff JH; Rushing EJ; Britschgi C; Curioni-Fontecedro A
Target Oncol; 2022 Nov; 17(6):683-694. PubMed ID: 36136211
[TBL] [Abstract][Full Text] [Related]
35. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
[TBL] [Abstract][Full Text] [Related]
36. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315).
Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F;
Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226
[TBL] [Abstract][Full Text] [Related]
37. Identification of transcriptional subgroups in EGFR-mutated and EGFR/KRAS wild-type lung adenocarcinoma reveals gene signatures associated with patient outcome.
Planck M; Isaksson S; Veerla S; Staaf J
Clin Cancer Res; 2013 Sep; 19(18):5116-26. PubMed ID: 23938291
[TBL] [Abstract][Full Text] [Related]
38. KRAS G12C-Mutant Non-Small Cell Lung Cancer: Biology, Developmental Therapeutics, and Molecular Testing.
Veluswamy R; Mack PC; Houldsworth J; Elkhouly E; Hirsch FR
J Mol Diagn; 2021 May; 23(5):507-520. PubMed ID: 33618059
[TBL] [Abstract][Full Text] [Related]
39. Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.
Redig AJ; Capelletti M; Dahlberg SE; Sholl LM; Mach S; Fontes C; Shi Y; Chalasani P; Jänne PA
Clin Cancer Res; 2016 Jul; 22(13):3148-56. PubMed ID: 26861459
[TBL] [Abstract][Full Text] [Related]
40. Response rate of patients with baseline brain metastases from recently diagnosed non-small cell lung cancer receiving radiotherapy according to EGFR, ALK and KRAS mutation status.
Arrieta O; Ramírez-Tirado LA; Caballé-Perez E; Mejia-Perez A; Zatarain-Barrón ZL; Cardona AF; Lozano-Ruíz F; Segura-González M; Cruz-Rico G; Maldonado F; Rosell R
Thorac Cancer; 2020 Apr; 11(4):1026-1037. PubMed ID: 32072746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]